Presentation is loading. Please wait.

Presentation is loading. Please wait.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Published byLenard Jennings Modified over 6 years ago

Similar presentations

Presentation on theme: "Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing."— Presentation transcript:

1 Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation  Nigel Pereira, M.D., Amelia G. Kelly, B.S., Logan D. Stone, B.A., Justine D. Witzke, Ph.D., M.P.H., Jovana P. Lekovich, M.D., Rony T. Elias, M.D., Glenn L. Schattman, M.D., Zev Rosenwaks, M.D.  Fertility and Sterility  Volume 108, Issue 3, Pages (September 2017) DOI: /j.fertnstert Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions

2 Figure 1 Comparison of E2 to MII oocyte, gonadotropin to MII oocyte (A), MII oocyte to AMH, 2PN embryo to AMH, MII oocyte to AFC, and 2PN embryo to AFC (B) ratios in cancer patients undergoing ovarian stimulation with letrozole-based protocols (n = 269). Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions

3 Figure 2 Comparison of E2 to MII oocyte, gonadotropin to MII oocyte (A), MII oocyte to AMH, and MII oocyte to AFC (B) ratios in cancer patients undergoing ovarian stimulation with gonadotropin-only protocols (n = 72). Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2017 American Society for Reproductive Medicine Terms and Conditions

Download ppt "Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing."

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.
Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase  Michael von Wolff, M.D., Christian J. Thaler,

Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase  Michael von Wolff, M.D., Christian J. Thaler,
Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 

Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 
Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D.  Fertility and Sterility 

Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D.  Fertility and Sterility 
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women  Carlos Iglesias, M.D., Manish Banker, M.D.,

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women  Carlos Iglesias, M.D., Manish Banker, M.D.,
Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study  Nicole Hope, M.B., B.S., Hon., Luk.

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study  Nicole Hope, M.B., B.S., Hon., Luk.
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.
Live birth of twins derived from zona-free oocytes

Live birth of twins derived from zona-free oocytes
The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count  Simone L. Broer, B.Sc., Ben Willem J.

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count  Simone L. Broer, B.Sc., Ben Willem J.
Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.

Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.

Similar presentations

Ads by Google